Test Price
2,800 AED✅ Home Collection Available
TYRP1 Gene Albinism, Oculocutaneous Type 3 (OCA3) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
This definitive next-generation sequencing (NGS) test analyzes the entire TYRP1 gene to confirm or exclude a diagnosis of oculocutaneous albinism type 3 (OCA3). Priced at 2,800 AED with a 3–4 week turnaround, it is performed under strict ISO 9001:2015 standards and DHA facility license 1143 at DNA Labs UAE, Dubai Healthcare City.
- Diagnostic Accuracy: 99.9% sensitivity and specificity via NGS, validated by an ISO‑accredited laboratory with Sanger confirmation.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post‑test clinical interpretation with a DHA‑licensed consultant medical geneticist.
- Insurance Assistance: Direct billing verification via WhatsApp at +971 54 548 8731.
Corporate Lab Branding: DNA Labs UAE | DHA Facility License: 1143 | Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Test Overview & Methodology
The TYRP1 gene test detects pathogenic variants causing oculocutaneous albinism type 3, a rare autosomal recessive disorder presenting with reduced pigmentation of skin, hair, and eyes. Using whole‑gene NGS with copy number variant analysis, we achieve unparalleled variant detection, far surpassing older PCR‑based methods. Below is a comparison that solidifies this test as the UAE’s definitive choice for OCA3 diagnosis.
| Feature | Our NGS TYRP1 Test (OCA3) | Closest Alternative (PCR / Panel) |
|---|---|---|
| Precision & Coverage | Complete gene sequencing (coding + splicing regions) with copy number variant analysis | Targeted hotspots only; misses deep intronic and large deletions |
| Methodology | Next‑Generation Sequencing (Illumina NovaSeq) with Sanger confirmation | Multiplex ligation‑dependent probe amplification (MLPA) or targeted Sanger |
| Turnaround Time | 3–4 weeks | 4–6 weeks (often delayed at non‑ISO labs) |
| Clinical Utility | Definitive diagnosis, family cascade testing, reproductive planning | Limited negative predictive value; often requires retesting |
Physician Insight & Safety Protocols
“Genetic test results must always be interpreted within the full clinical and family history. A positive TYRP1 variant confirms the subtype but does not predict the exact severity of hypopigmentation. I strongly recommend pre‑ and post‑test genetic counselling to ensure complete understanding and emotional preparedness. Your multidisciplinary team is here to guide you through every step.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Safety Advisory
Medication & Clinical Management
Do not discontinue any prescribed medication or topical therapy without consulting your physician. The test result does not replace clinical management. Always consult your treating specialist before making any changes to your care plan based on genetic findings.
Patient Exclusion Criteria & Emergency Red Flags
Safety & Exclusion Guidelines
- Exclusion: Active febrile illness or systemic infection on the day of sample collection; patients with a known bleeding disorder unless cleared by their haematologist.
- Minors: Testing of individuals under 18 years requires a valid consent form signed by a parent or legal guardian and witnessed by a DHA‑licensed physician in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Sample Integrity: Peripheral whole blood or buccal swab specimens must be collected by our certified phlebotomy team to avoid degradation; self‑collected FTA cards are not accepted.
- Red Flags – Seek Immediate Medical Attention: If after venipuncture you experience excessive bleeding, swelling, or signs of infection (redness, pus, fever), go to the nearest emergency department and inform the laboratory.
- Emotional Wellbeing: Genetic testing can provoke anxiety; if you feel overwhelmed, the DHA mental health helpline 800‑42‑800 is available.
Patient FAQ & Clinical Guidance
1. How accurate is this TYRP1 test for diagnosing OCA3, and can it detect all mutations?
Our NGS test sequences the entire TYRP1 gene with read depth >100x, ensuring >99.9% diagnostic sensitivity for single nucleotide variants, small insertions/deletions, and copy number variations. It will identify the causative mutation in over 98% of clinically diagnosed OCA3 cases. In rare instances of deep intronic or regulatory mutations, a full‑genome approach may be supplemented after genetic counselling.
2. Why does the test take 3–4 weeks, and can I get results faster?
Because each sample undergoes library preparation, bidirectional NGS, and confirmatory bioinformatics analysis, the standard turnaround is 3–4 weeks to guarantee precision. Rush options up to 2 weeks are available for an additional fee and must be pre‑approved by the laboratory director. We never compromise on the ISO‑required quality checks.
3. Is my genetic data kept confidential, and can it be shared with insurers or employers?
Under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, your genetic data is classified as sensitive personal data—never shared without explicit consent. We store it on encrypted, ISO 27001‑certified servers within the UAE. Genetic counselling reports are only released to the ordering physician and the patient or guardian.
UAE Regulatory & Data Privacy Adherence
Legal & Privacy Compliance Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): governs the collection, processing, and storage of genetic data as sensitive personal information, requiring explicit patient consent and purpose limitation.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: mandates cybersecurity standards for health information systems, ensuring encrypted transmission and access controls for all genomic data.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: establishes the legal framework for informed consent, clinical responsibility, and patient safety in diagnostic genetic testing.
All testing is performed at DNA Labs UAE under DHA Facility License 1143, located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | TYRP1 Gene Albinism, Oculocutaneous Type 3 (OCA3) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Buccal Swab; VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available Daily 8 AM – 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq with Sanger Confirmation and Copy Number Variant Analysis |
| ICD-10-CM Code | E70.330 |
| LOINC Code | 94853-9 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians